Recent evidence indicates that small compounds or peptides that interfere with the interaction between the TPR2A domain of STIP1 and the MEEVD motif of HSP90 can display anti-cancer activity both in vitro and in vivo [38]. The gene discussed is STIP1; the disease is cancer.